CN1977856A - Clindamycin palmitate hydrochloride chewing tablet andi its preparing method - Google Patents
Clindamycin palmitate hydrochloride chewing tablet andi its preparing method Download PDFInfo
- Publication number
- CN1977856A CN1977856A CN 200510129857 CN200510129857A CN1977856A CN 1977856 A CN1977856 A CN 1977856A CN 200510129857 CN200510129857 CN 200510129857 CN 200510129857 A CN200510129857 A CN 200510129857A CN 1977856 A CN1977856 A CN 1977856A
- Authority
- CN
- China
- Prior art keywords
- clindamycin
- palmitate
- hydrochloride
- andi
- chewing tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a clindamicin palmitate masticatory tablet and its preparation method. It is characterized by that it adopts dry granulation process so as to maximally retain the activity of clindamicin palmitate, it is easy to implement industrial production and its preparation process is simple.
Description
Technical field
The present invention relates to treat clindamycin palmitate hydrochloride chewing tablet andi of the kind infectious disease that causes by aerobic G+ bacterium and anaerobe and chlamydia, protozoon etc. and preparation method thereof.
Background technology
Clindamycin hydrochloride palmitate is a kind of antibacterials of being succeeded in developing by general strong (Upjohn) company, and commodity are called Cleocin Pediatric , and external peroral dosage form mainly is a dry syrup.Domesticly develop this product granule in the nineties, earlier 1900s is developed this product tablet formulation.
Clindamycin palmitate hydrochloride chewing tablet andi is the prodrug of clindamycin, and oral back absorption rapidly also is hydrolyzed to reactive precursor in vivo and brings into play curative effect.Clindamycin hydrochloride palmitate has the unique chemical structure, is not subjected to the influence of beta-lactamase, and is still effective to the Resistant strain of part penicillin resistant, cephalosporin, erythromycin, tetracycline, and mechanism of action is synthetic for suppressing bacterioprotein.The clindamycin hydrochloride palmitate antibacterial action is strong, and aerobic G+ bacterium and anaerobe and chlamydia, protozoon are all had the strong antibiotic effect.Clindamycin hydrochloride palmitate excellent absorption and extensive tissue distribution characteristic, clinical pulmonary infection, bone joint infection, otorhinolaryngology infection, abdominal cavity infection, pelvic infection, protozoan infection and periodontal disease, the skin soft-tissue infection of being widely used in all has curative effect preferably.Clindamycin hydrochloride palmitate similar medicine has abroad recorded the pharmacopeia into American-European developed country, and good safety is arranged, and is particularly suitable to penicillin, cephalosporin patient hypersensitive.
Clindamycin hydrochloride palmitate is compared with clindamycin, indication is basic identical, modification by chemical constitution, clindamycin hydrochloride palmitate has not had the bitterness of clindamycin, and easier absorption, side effect is littler than Clindamycin Hydrochloride, and patient's better tolerance is so be suitable for child and gerontal patient's medication especially.At present, domestic only have the clindamycin hydrochloride palmitate granule that Xi-nan Synthetic Medicine Factory produces (trade name: but youngster gives birth to) and the clindamycin palmitate hydrochloride dispersion tablet of Chongqing Carelife Pharmaceutical Co., Ltd.'s production (trade name: Kai Laikelin) appear on the market, dosage form be single.In order to enrich the kind of clindamycin hydrochloride palmitate, make the patient that more dosage form selection leeway be arranged, this shows that the present invention will have vast market prospect.
Summary of the invention
In order to solve the single shortcoming of prior art clindamycin hydrochloride palmitate peroral dosage form; Improve its bioavailability; Make the patient that more dosage form selection leeway be arranged; The toxic and side effects that reduces medicine is the purpose that the present invention develops clindamycin palmitate hydrochloride chewing tablet andi.
Another object of the present invention provides the method for preparing clindamycin palmitate hydrochloride chewing tablet andi.
The object of the present invention is achieved like this: (a) clindamycin hydrochloride palmitate is crossed the 40-60 mesh sieve, and used adjuvant is crossed the 60-80 mesh sieve, and is standby; (b) take by weighing the clindamycin hydrochloride palmitate and the adjuvant of recipe quantity; (c) place blender to be mixed to evenly clindamycin hydrochloride palmitate, mannitol, Icing Sugar, solubilizing agent, correctives, Pulvis Talci etc., grind the squeezing and pressing method granulation, cross 10-40 mesh sieve granulate, must do granule with rolling; (d) add magnesium stearate and essence in the granule that (c) makes, behind the mix homogeneously, tabletting after airtight 0.5-3 hour makes chewable tablet.
Compared with prior art, the present invention has following advantage:
1, the present invention makes clindamycin hydrochloride palmitate stripping more fully owing to added as solubilizing agents such as poloxamer, PEG4000, makes that absorption of human body is fast, bioavailability is high;
2, be convenient to patient and take, chew, suck clothes or swallow, patient not water also can take, the inconvenient patient of conventional tablet that is specially adapted to swallow, and the present invention is fragrant and sweet good to eat after seasoning, is convenient to patient and uses, and compliance is good;
3, it to have solved peroral dosage form single, the problem of granule and dispersible tablet only arranged, enriched doctor, patient's dosage form selection leeway;
4, adopt dry granulation, preserved the activity of clindamycin hydrochloride palmitate to greatest extent, and be easy to suitability for industrialized production, technology is easy.
The invention will be further described below in conjunction with the specific embodiment.
The specific embodiment
To further illustrate the present invention in following examples, these embodiment only are used to the present invention is described and to the present invention without limits.
Embodiment 1:
1, the prescription of clindamycin palmitate hydrochloride chewing tablet andi is composed as follows: (37.5mg specification in 1000) wherein contains:
Clindamycin hydrochloride palmitate 37.5g (in clindamycin)
Mannitol 250g
Icing Sugar 50g
Poloxamer 10g
Steviosin 5g
Pulvis Talci 10g
Magnesium stearate 15g
Essence 20ml
2, the clindamycin palmitate hydrochloride chewing tablet andi preparation method is as follows:
(a) clindamycin hydrochloride palmitate is crossed the 40-60 mesh sieve, and used adjuvant is crossed the 60-80 mesh sieve, and is standby; (b) take by weighing the clindamycin hydrochloride palmitate and the adjuvant of recipe quantity; (c) place blender to be mixed to evenly clindamycin hydrochloride palmitate, mannitol, Icing Sugar, solubilizing agent, correctives, Pulvis Talci etc., grind the squeezing and pressing method granulation, cross 10-40 mesh sieve granulate, must do granule with rolling; (d) add magnesium stearate and essence in the granule that (c) makes, behind the mix homogeneously, tabletting after airtight 0.5-3 hour makes chewable tablet.
Sampling then, detection level and dissolution and hardness all meet relevant drug standard.
Embodiment 2:
1, the prescription of clindamycin palmitate hydrochloride chewing tablet andi is composed as follows: (75mg specification in 1000) wherein contains:
Clindamycin hydrochloride palmitate 75g (in clindamycin)
Mannitol 200g
Icing Sugar 40g
Poloxamer 15g
Steviosin 5g
Pulvis Talci 10g
Magnesium stearate 15g
Essence 25ml
2, clindamycin palmitate hydrochloride chewing tablet andi preparation method one, two is with embodiment 1.
Embodiment 3:
1, the prescription of clindamycin palmitate hydrochloride chewing tablet andi is composed as follows: (150mg specification in 1000) wherein contains:
Clindamycin hydrochloride palmitate 150g (in clindamycin)
Mannitol 160g
Icing Sugar 40g
Poloxamer 30g
Steviosin 6g
Pulvis Talci 10g
Magnesium stearate 15g
Essence 30ml
2, clindamycin palmitate hydrochloride chewing tablet andi preparation method one, two is with embodiment 1.
Embodiment 4:
1, the prescription of clindamycin palmitate hydrochloride chewing tablet andi is composed as follows: (300mg specification in 1000) wherein contains:
Clindamycin hydrochloride palmitate 300g (in clindamycin)
Mannitol 120g
Icing Sugar 30g
Poloxamer 35g
Steviosin 8g
Pulvis Talci 15g
Magnesium stearate 20g
Essence 40ml
2, clindamycin palmitate hydrochloride chewing tablet andi preparation method one, two is with embodiment 1.
Embodiment 5:
1, the prescription of clindamycin palmitate hydrochloride chewing tablet andi is composed as follows: (75mg specification in 1000) wherein contains:
Clindamycin hydrochloride palmitate 75g (in clindamycin)
Sorbitol 200g
Icing Sugar 40g
Poloxamer 15g
Steviosin 5g
Pulvis Talci 10g
Magnesium stearate 15g
Fructus Citri Limoniae essence 25ml
2, clindamycin palmitate hydrochloride chewing tablet andi preparation method one, two is with embodiment 1.
Embodiment 6:
1, the prescription of clindamycin palmitate hydrochloride chewing tablet andi is composed as follows: (75mg specification in 1000) wherein contains:
Clindamycin hydrochloride palmitate 75g (in clindamycin)
Sorbitol 200g
Icing Sugar 40g
Poloxamer 15g
Aspartame 5g
Pulvis Talci 10g
Magnesium stearate 15g
Orange flavor 25ml
2, clindamycin palmitate hydrochloride chewing tablet andi preparation method one, two is with embodiment 1.
Claims (9)
1, a kind of clindamycin palmitate hydrochloride chewing tablet andi is characterized in that: every contains the clindamycin hydrochloride palmitate that is equivalent to 30-350mg (in clindamycin); The pharmaceutic adjuvant that also comprises other comprises filler, solubilizing agent, correctives, adhesive, lubricant etc.
2, clindamycin palmitate hydrochloride chewing tablet andi as claimed in claim 1 is characterized in that described solubilizing agent is: poloxamer, PEG-4000 etc.
3, clindamycin palmitate hydrochloride chewing tablet andi as claimed in claim 1 is characterized in that described correctives is: steviosin, aspartame etc.
4, as arbitrary clindamycin palmitate hydrochloride chewing tablet andi of claim 1 to 3, its prescription is composed as follows: in 1000, wherein contain
Clindamycin hydrochloride palmitate 30g-350g (in clindamycin)
Mannitol 50-300g
Icing Sugar 30-100g
Solubilizing agent 10-50g
Correctives 5-20g
Pulvis Talci 10-30g
Magnesium stearate 10-30g
Essence 10-50ml.
5,, it is characterized in that every dosage that contains described clindamycin hydrochloride palmitate counts 37.5mg with clindamycin as the described clindamycin palmitate hydrochloride chewing tablet andi of claim 1 to 4.
6,, it is characterized in that every dosage that contains described clindamycin hydrochloride palmitate counts 75mg with clindamycin as the described clindamycin palmitate hydrochloride chewing tablet andi of claim 1 to 4.
7,, it is characterized in that every dosage that contains described clindamycin hydrochloride palmitate counts 150mg with clindamycin as the described clindamycin palmitate hydrochloride chewing tablet andi of claim 1 to 4.
8,, it is characterized in that every dosage that contains described clindamycin hydrochloride palmitate counts 300mg with clindamycin as the described clindamycin palmitate hydrochloride chewing tablet andi of claim 1 to 4.
9,, it is characterized in that comprising the steps: as the preparation method of the described clindamycin palmitate hydrochloride chewing tablet andi of claim 1 to 8
(a) take by weighing the clindamycin hydrochloride palmitate and the adjuvant of recipe quantity;
(b) place blender to be mixed to evenly clindamycin hydrochloride palmitate, mannitol, Icing Sugar, solubilizing agent, correctives, Pulvis Talci etc., grind the squeezing and pressing method granulation with rolling;
(c) add magnesium stearate and essence in the granule that (b) makes, behind the mix homogeneously, tabletting after airtight 0.5-3 hour makes chewable tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101298574A CN100566721C (en) | 2005-12-09 | 2005-12-09 | Clindamycin palmitate hydrochloride chewing tablet andi and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005101298574A CN100566721C (en) | 2005-12-09 | 2005-12-09 | Clindamycin palmitate hydrochloride chewing tablet andi and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1977856A true CN1977856A (en) | 2007-06-13 |
| CN100566721C CN100566721C (en) | 2009-12-09 |
Family
ID=38129276
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005101298574A Expired - Fee Related CN100566721C (en) | 2005-12-09 | 2005-12-09 | Clindamycin palmitate hydrochloride chewing tablet andi and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100566721C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010010568A1 (en) * | 2008-07-22 | 2010-01-28 | Lupin Limited | Oral compositions of clindamycin |
-
2005
- 2005-12-09 CN CNB2005101298574A patent/CN100566721C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010010568A1 (en) * | 2008-07-22 | 2010-01-28 | Lupin Limited | Oral compositions of clindamycin |
| US9040089B2 (en) | 2008-07-22 | 2015-05-26 | Lupin Limited | Oral compositions of clindamycin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100566721C (en) | 2009-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7070805B2 (en) | Rapidly disintegrable solid preparation | |
| US20100215740A1 (en) | Taste-masked orally disintegrating tablets of memantine hydrochloride | |
| KR101435229B1 (en) | Orally disintegrating tablet and process for production thereof | |
| CN101352424A (en) | Cefdinir dispersible tablet and preparation method thereof | |
| KR20010024464A (en) | Quickly soluble solid preparations | |
| KR20150003740A (en) | Orally disintegrating tablet and method for producing same | |
| CN1911211B (en) | Solid oral preparation of leishajilan | |
| WO2013058496A1 (en) | Taste-masked pharmaceutical composition for oral administration and a process for the preparation thereof | |
| CN103520124B (en) | A kind of Levofloxacin Tablet and preparation method thereof | |
| CN102631329A (en) | Oral paroxetine disintegrating tablet and preparation process thereof | |
| CN100566721C (en) | Clindamycin palmitate hydrochloride chewing tablet andi and preparation method thereof | |
| CN100356925C (en) | Clindamycin palmitate hydrochloride dispersion tablet and its preparation method | |
| CN102727456B (en) | Drug port cavity disintegrating tablet and preparation method thereof | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN101612152A (en) | A kind of pharmaceutical composition that contains pidotimod and preparation method thereof | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN101444513A (en) | Cefaclor orally disintegrating tablet and preparation method thereof | |
| US20070014850A1 (en) | Process for the preparation of dispersible tablets of cephalexin | |
| CN100553635C (en) | Contain the pharmaceutical composition and the application thereof of amoxicillin, ambroxol and beta lactamase restrainer | |
| WO2007125541A1 (en) | Pharmaceutical compositions of cefdinir | |
| CN102058587A (en) | Solid preparation for treating asthma | |
| CN100415243C (en) | Composition of water soluble Azithromycin salt | |
| CN102772455A (en) | Seabuckthorn flavone dispersible tablets | |
| CN1857296A (en) | Medicine composition with roxithromycin and ambroxol hydrochloride as active components and its preparing method and use | |
| JPH11116465A (en) | Rapidly dissolvable preparation and its production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091209 Termination date: 20111209 |